Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc.

Case: 21-2024 Document: 55 Page: 1 Filed: 02/15/2022

NOTE: This disposition is nonprecedential. United States Court of Appeals for the Federal Circuit

______________________

AMARIN PHARMA, INC., AMARIN

PHARMACEUTICALS IRELAND LIMITED,

Plaintiffs

EPA DRUG INITIATIVE II, Movant-Appellant v.

HIKMA PHARMACEUTICALS USA INC., HIKMA PHARMACEUTICALS INTERNATIONAL LIMITED,

WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED, DR. REDDY'S LABORATORIES, INC., DR. REDDY'S

LABORATORIES, LTD., Defendants-Appellees ______________________

2021-2024 ______________________

Appeal from the United States District Court for the District of Nevada in Nos. 2:16-cv-02525-MMD-NJK, 2:16- cv-02562-MMD-NJK, Judge Miranda M. Du.

______________________ JUDGMENT ______________________

Case: 21-2024 Document: 55 Page: 2 Filed: 02/15/2022

MICHAEL S. KASANOFF, I, Michael S. Kasanoff, LLC, Matawan, NJ, argued for movant-appellant.

CHARLES B. KLEIN, Winston & Strawn LLP, Washing- ton, DC, for defendants-appellees Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals International Limited, West-Ward Pharmaceuticals International Limited. Also represented by CLAIRE A. FUNDAKOWSKI; ALISON MICHELLE KING, Chicago, IL; EIMERIC REIG-PLESSIS, San Francisco, CA.

JAMES BARABAS, Windels Marx Lane & Mittendorf, LLP, Madison, NJ, argued for all defendants-appellees. Defendants-appellees Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. also represented by BETH C. FINKELSTEIN, CONSTANCE HUTTNER, CAROLINE SUN.

______________________

THIS CAUSE having been heard and considered, it is ORDERED and ADJUDGED:

PER CURIAM (NEWMAN, DYK, and REYNA, Circuit Judges).

AFFIRMED. See Fed. Cir. R. 36.

ENTERED BY ORDER OF THE COURT February 15, 2022 /s/ Peter R. Marksteiner

Date Peter R. Marksteiner

Clerk of Court